{"id":"W2741548122","doi":"10.1158/1538-7445.am2017-ct046","title":"Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with <i>RAS</i> mutant solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Palbociclib; Medicine; Tolerability; Pharmacokinetics; Pharmacology; Neutropenia; Leukopenia; Internal medicine; Oncology; Cancer; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008035792,0.001596101,0.001529973,0.0006197832,0.0004323697,0.000985657,0.0008892675,0.0007873898,0.003438128],"category_scores_gemma":[0.0005636702,0.0006164261,0.0008723899,0.0005454035,0.0007595486,0.0006739223,0.0003124725,0.003118942,0.0009809897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00118916,"about_ca_system_score_gemma":0.001734303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001410791,"about_ca_topic_score_gemma":0.003485749,"domain_scores_codex":[0.9996949,0.0001189596,0.00001950944,0.00005397404,0.00004550214,0.00006712695],"domain_scores_gemma":[0.99965,0.00003953222,0.00007393032,0.00002696184,0.00003064992,0.0001789608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5436633,0.09727081,0.01429992,0.001002805,0.001782801,0.0005804347,0.0004681374,0.007278509,0.183321,0.0005422137,0.007933363,0.1418566],"study_design_scores_gemma":[0.3516878,0.6014785,0.02169948,0.00004413858,0.0005597593,0.0006365635,0.00009376327,0.003543906,0.01650799,0.0001776581,0.003518236,0.00005228077],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939329,0.001006079,0.0004532285,0.0002707058,0.00006086111,0.001461066,0.0009451256,0.0001483112,0.001721636],"genre_scores_gemma":[0.9928892,0.0006568792,0.00137586,0.0002885447,0.00007441588,0.001213708,0.00159019,0.000023165,0.001887931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003438128,"threshold_uncertainty_score":0.01150167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03961281957013143,"score_gpt":0.3934869420847642,"score_spread":0.3538741225146328,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}